Vytrus Biotech

vytrus.com

Biotech company specialized in the development, production and commercialization of high added value active ingredients from the technology of plant stem cells, for cosmetics and dermocosmetics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

news image

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More

BIOLINERX ANNOUNCES POSITIVE RESULTS FROM A PLANNED INTERIM ANALYSIS OF THE ONGOING GENESIS PHASE 3 TRIAL OF MOTIXAFORTIDE FOR STEM CELL MOBILIZATION

BioLineRx | October 30, 2020

news image

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically sig...

Read More

Cell and Gene Therapy

EVONETIX DEMONSTRATES NOVEL ENZYMATIC DNA SYNTHESIS METHOD

EVONETIX LTD | March 02, 2022

news image

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabli...

Read More

MedTech

SALIPRO BIOTECH RECEIVES EUROPEAN PATENT FOR ANTIGEN PRODUCTION

Salipro Biotech | February 09, 2022

news image

Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled "Antigen and method for production thereof", following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. The patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform te...

Read More
news image

MedTech

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More
news image

BIOLINERX ANNOUNCES POSITIVE RESULTS FROM A PLANNED INTERIM ANALYSIS OF THE ONGOING GENESIS PHASE 3 TRIAL OF MOTIXAFORTIDE FOR STEM CELL MOBILIZATION

BioLineRx | October 30, 2020

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically sig...

Read More
news image

Cell and Gene Therapy

EVONETIX DEMONSTRATES NOVEL ENZYMATIC DNA SYNTHESIS METHOD

EVONETIX LTD | March 02, 2022

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabli...

Read More
news image

MedTech

SALIPRO BIOTECH RECEIVES EUROPEAN PATENT FOR ANTIGEN PRODUCTION

Salipro Biotech | February 09, 2022

Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled "Antigen and method for production thereof", following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. The patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform te...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us